恩杂鲁胺和阿比特龙在转移性去势抵抗性前列腺癌一线和二线治疗中的实际总生存率比较。

IF 2.6 3区医学 Q3 ENDOCRINOLOGY & METABOLISM

Prostate Pub Date : 2025-09-01 Epub Date: 2025-06-08 DOI:10.1002/pros.24923

András Horváth, Celia Blasszauer, Ida Komka, Dániel Reibl, Boris Hadaschik, Tamás Fazekas, Pawel Rajwa, Àron Soós, Anikó Valikovics, Péter Nyirády, Tibor Szarvas

{"title":"恩杂鲁胺和阿比特龙在转移性去势抵抗性前列腺癌一线和二线治疗中的实际总生存率比较。","authors":"András Horváth, Celia Blasszauer, Ida Komka, Dániel Reibl, Boris Hadaschik, Tamás Fazekas, Pawel Rajwa, Àron Soós, Anikó Valikovics, Péter Nyirády, Tibor Szarvas","doi":"10.1002/pros.24923","DOIUrl":null,"url":null,"abstract":"Background: While their indications overlap, no clinical trials have compared abiraterone and enzalutamide for overall survival (OS) in mCRPC.Methods: A large, country-wide health insurance database (2013-2023) was assessed for the OS comparison between abiraterone and enzalutamide.Results: Overall, 3497 patients were identified with first- (n = 2215) or second-line (n = 1282) abiraterone or enzalutamide treatment (only 66 received both drugs sequentially). Enzalutamide-treated patients had longer OS both in the first- (HR:0.84; 95%CI:0.74-0.96; p = 0.008) and the second-line setting (HR:0.88; 95%CI:0.78-0.99; p = 0.043), respectively.Conclusions: This health insurance-registry-based study suggests that, in the real-world mCRPC setting, enzalutamide is superior to abiraterone in terms of OS.","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"1151-1154"},"PeriodicalIF":2.6000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278699/pdf/","citationCount":"0","resultStr":"{\"title\":\"Real-World Overall Survival Comparison of Enzalutamide and Abiraterone In First- and Second-Line Setting of Metastatic Castration-Resistant Prostate Cancer.\",\"authors\":\"András Horváth, Celia Blasszauer, Ida Komka, Dániel Reibl, Boris Hadaschik, Tamás Fazekas, Pawel Rajwa, Àron Soós, Anikó Valikovics, Péter Nyirády, Tibor Szarvas\",\"doi\":\"10.1002/pros.24923\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: While their indications overlap, no clinical trials have compared abiraterone and enzalutamide for overall survival (OS) in mCRPC.Methods: A large, country-wide health insurance database (2013-2023) was assessed for the OS comparison between abiraterone and enzalutamide.Results: Overall, 3497 patients were identified with first- (n = 2215) or second-line (n = 1282) abiraterone or enzalutamide treatment (only 66 received both drugs sequentially). Enzalutamide-treated patients had longer OS both in the first- (HR:0.84; 95%CI:0.74-0.96; p = 0.008) and the second-line setting (HR:0.88; 95%CI:0.78-0.99; p = 0.043), respectively.Conclusions: This health insurance-registry-based study suggests that, in the real-world mCRPC setting, enzalutamide is superior to abiraterone in terms of OS.\",\"PeriodicalId\":54544,\"journal\":{\"name\":\"Prostate\",\"volume\":\" \",\"pages\":\"1151-1154\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278699/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Prostate\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/pros.24923\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/6/8 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prostate","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pros.24923","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/8 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

摘要

背景：虽然它们的适应症重叠，但没有临床试验比较阿比特龙和恩杂鲁胺对mCRPC的总生存期（OS）。方法：对2013-2023年全国范围内的大型健康保险数据库进行评估，比较阿比特龙和恩杂鲁胺的OS。结果：总的来说，3497名患者接受了一线（n = 2215）或二线（n = 1282）阿比特龙或恩杂鲁胺治疗（只有66名患者同时接受了这两种药物）。enzalutamide治疗的患者在第一次- (HR:0.84；95%置信区间:0.74—-0.96;p = 0.008)和二线组(HR:0.88；95%置信区间:0.78—-0.99;P = 0.043)。结论：这项基于健康保险登记的研究表明，在现实世界的mCRPC环境中，恩杂鲁胺在OS方面优于阿比特龙。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Real-World Overall Survival Comparison of Enzalutamide and Abiraterone In First- and Second-Line Setting of Metastatic Castration-Resistant Prostate Cancer.

Background: While their indications overlap, no clinical trials have compared abiraterone and enzalutamide for overall survival (OS) in mCRPC.

Methods: A large, country-wide health insurance database (2013-2023) was assessed for the OS comparison between abiraterone and enzalutamide.

Results: Overall, 3497 patients were identified with first- (n = 2215) or second-line (n = 1282) abiraterone or enzalutamide treatment (only 66 received both drugs sequentially). Enzalutamide-treated patients had longer OS both in the first- (HR:0.84; 95%CI:0.74-0.96; p = 0.008) and the second-line setting (HR:0.88; 95%CI:0.78-0.99; p = 0.043), respectively.

Conclusions: This health insurance-registry-based study suggests that, in the real-world mCRPC setting, enzalutamide is superior to abiraterone in terms of OS.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Prostate 医学-泌尿学与肾脏学

CiteScore

5.10

自引率

3.60%

发文量

180

审稿时长

1.5 months

期刊介绍： The Prostate is a peer-reviewed journal dedicated to original studies of this organ and the male accessory glands. It serves as an international medium for these studies, presenting comprehensive coverage of clinical, anatomic, embryologic, physiologic, endocrinologic, and biochemical studies.